Showing results (1471-1480 of 3,105) with videos related to

Sort By:
Pageof 311
Drug Safety|July 9, 2025
Real-World Data Insights into Antidepressant Prescription and Adherence During Pregnancy in Catalonia (Spain)Lucía Bellas, Lina Camacho-Arteaga, Maria Giner-Soriano, et al.
Drug Safety|July 7, 2025
Temporal Changes in Reporting of Neurodevelopmental Outcomes After Maternal Exposure to Valproate: A Contribution of the ConcePTION ProjectDimitra Gkolfi, Yrea R J van Rijt-Weetink, Henric Taavola-Gustafsson, et al.
Drug Safety|September 25, 2025
Content Analysis of Promotional Materials for Prescription Drugs Authorized Under Emergency Use AuthorizationBridget Kelly, Kathryn J Aikin, Helen W Sullivan, et al.
Drug Safety|September 15, 2025
The Development and Use of Office of New Drugs Custom Medical Queries for Safety Analyses of Clinical Trial DataScott Proestel, Vaishali Popat, Ellis F Unger, et al.
Drug Safety|May 18, 2025
Risk of New-Onset Atrial Fibrillation in Opioid Users: A Systematic Review and Meta-Analysis on 24,006,367 ParticipantsDanilo Menichelli, Gianluca Gazzaniga, Arianna Pannunzio, et al.
Drug Safety|August 9, 2025
Pharmacovigilance in Cell and Gene Therapy: Evolving Challenges in Risk Management and Long-Term Follow-UpEmile Youssef, Kari Weddle, Lisa Zimmerman, et al.
Drug Safety|October 6, 2025
Harm to Children from Prescribing and Administration Errors in Acute Care: A Multidisciplinary Panel AssessmentVirginia Mumford, Magdalena R Raban, Erin Fitzpatrick, et al.
Drug Safety|September 12, 2025
Comparative Risk of Acute Kidney Injury with Piperacillin-Tazobactam Plus Teicoplanin Versus Piperacillin-Tazobactam Plus Vancomycin: A Systematic Review and Meta-AnalysisShahd Mohammad, Haneen Ghazal, Wafaa Rahimeh, et al.
Drug Safety|August 12, 2025
The Extent and Magnitude of Bias in Case-Crossover Studies of Real-World Non-transient Medications Patterns: A Simulation Study with Real-World ExamplesHsiao-Ching Huang, Mina Tadrous, Saria Awadalla, et al.
Drug Safety|January 27, 2026
Physician Awareness of FDA's Relaxation of REMS-Required Laboratory Testing Requirements and Changes in Prescribing Practices During the COVID-19 PandemicCatherine S Hwang, Zhigang Lu, Massimiliano Russo, et al.
Pageof 311